Sheldon Claire A, Reggie Sara N, Paley Grace L, McCormack Shana E, Liu Grant T
Department of Ophthalmology, University of British Columbia, Vancouver, BC, Canada.
Ophthalmic Plastic & Cosmetic Surgery, Inc., St. Louis, MO, United States.
Front Ophthalmol (Lausanne). 2023 Feb 6;2:1042529. doi: 10.3389/fopht.2022.1042529. eCollection 2022.
BACKGROUND/INTRODUCTION: While oral acetazolamide is a cornerstone of management of adult and pediatric PTCS, previous studies have suggested that acetazolamide used in children with other conditions may influence growth.
Retrospective chart review involving a single tertiary medical center. Thirty-four children with definite or probable PTCS were identified. Analysis was restricted to individuals from whom anthropometric data were available and acetazolamide treatment (n=22).
Half of individuals (n=11/22) showed a decline in BMI Z-scores. Sixty-three percent (n=14/22) showed a decrease in height Z-scores during treatment with acetazolamide; in 6 of these 14 children who had complete data, 3 showed at least a partial recovery of height Z-scores after discontinuation of acetazolamide.
Acetazolamide may be associated with growth suppression in some children treated for pediatric PTCS. In some cases, the growth suppression appears to reverse once the acetazolamide is stopped.
背景/引言：虽然口服乙酰唑胺是成人和儿童周期性呕吐综合征（PTCS）治疗的基石，但先前的研究表明，在患有其他疾病的儿童中使用乙酰唑胺可能会影响生长。
对一家单一的三级医疗中心进行回顾性病历审查。确定了34例确诊或可能患有PTCS的儿童。分析仅限于可获得人体测量数据且接受乙酰唑胺治疗的个体（n = 22）。
一半的个体（n = 11/22）的BMI Z评分下降。63%（n = 14/22）的个体在接受乙酰唑胺治疗期间身高Z评分下降；在这14例有完整数据的儿童中，有6例在停用乙酰唑胺后，3例的身高Z评分至少部分恢复。
在一些接受儿童PTCS治疗的儿童中，乙酰唑胺可能与生长抑制有关。在某些情况下，一旦停用乙酰唑胺，生长抑制似乎会逆转。
